TC-E202

TC-E202 is a first-in-class adoptive cell therapy developed for the treatment of HPV16-positive cervical cancer. It is a genetically engineered T cell receptor (TCR) therapy that incorporates both an HPV16 E6-specific TCR and the variable region fragments of an anti-PD-1 antibody. After viral transfection, patient-derived T cells are modified to express the HPV16 E6-specific TCR, enabling them to recognize and kill tumor cells expressing the HPV16 E6 antigen. Simultaneously, these modified cells secrete a PD-1 single-chain antibody fragment, which acts as an immune checkpoint inhibitor within the tumor microenvironment. This dual mechanism aims to enhance antitumor efficacy by both directly targeting tumor antigens and overcoming local immunosuppression mediated by PD-1/PD-L1 signaling. The primary indication under investigation is relapsed or refractory metastatic cervical carcinoma in HLA-A*02 positive patients who have failed standard therapies[1][2][4][5].

Other names

TC-E202TC-E-202TC-E 202